Key Pointsbluebird bio is a major beneficiary of gene therapy headlines as it has 3 FDA approval therapies.bluebird was a $158 stock in 2019, which has fallen as low as 87 cents in 2024.OTM LEAPS calls can be held while selling OTM front-month calls for income.5 stocks we like better than bluebird bioGene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT from CRISPR Therapeutics AG NASDAQ: CRSP and part ...

Key PointsHealthcare stocks quietly build momentum to bring the market's next potential rally; not all stocks are created equal.bluebird Bio stock is a particular case in this space, calling for a massive upside in price targets, and institutional buying could create the next big short squeeze. Management has set up the scene, and the writing is on the wall for its upcoming earnings announcement.5 stocks we like better than bluebird bioMaybe you are looking back at the 2020-2023 equity curve in your portfol ...

Key PointsGene therapy usually involves a one-time treatment but can cost from $2 million up to $3.5 million per patient.Like Gilead Sciences did with its hepatitis C drugs, gene therapy companies used value-based pricing to justify the high fees for novel therapies.Unlike Gilead's hepatitis C drugs, these gene therapy treatments have yet to cure rare diseases but instead care for the worst symptoms.5 stocks we like better than CRISPR TherapeuticsGene therapy treatments have been making major headlines as a ...

The past couple of years have been eventful for Bluebird Bio (BLUE -6.80%). In 2022, the gene-editing specialist earned approval for two therapies in the U.S.: Zynteglo, which treats the beta thalassemia (TDT) genetic blood condition, and Skysona, a treatment for cerebral adrenoleukodystrophy (CALD), an inherited disorder that attacks nerve sheaths in the brain. And last year, Bluebird Bio got the green light for yet another gene-editing treatment, Lyfgenia, which targets sickle cell disease (SCD). The appr ...

Investing in biotech stocks is a tricky and risky endeavor, but there's a lot investors can do to increase their chances of success -- or at least avoid total failure and the loss of their funds.Here are three quick tricks that'll help to guide your biotech investments. You'll find them to be the most useful when you're evaluating whether to buy shares of a given company, but they'll also help you to understand when one of your holdings is entering a risky period.1. Cash comes firstMany of the biggest oppor ...

Investors looking for stocks that can make dramatic gains fairly quickly got what they wanted from CRISPR Therapeutics (CRSP -0.34%) this year. The stock is up more than 60% in 2023 after the company earned Food and Drug Administration (FDA) approval for its first treatment, Casgevy.CRISPR Therapeutics is transitioning into a commercial-stage company. But new drug launches can be unpredictable, and Casgevy, which it developed with partner Vertex Pharmaceuticals (VRTX 0.10%), will be breaking a lot of new gr ...

bluebird bio, Inc. (NASDAQ:BLUE) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Courtney O'Leary - Director of Investor Relations Andrew Obenshain - Chief Executive Officer Tom Klima - Chief Commercial and Operating Officer Chris Krawtschuk - Chief Financial Officer Conference Call Participants Dane Leone - RJF Jason Gerberry - Bank of America Securities Eric Joseph - JPMorgan Jack Allen - Baird Gena Wang - Barclays Mani Foroohar - Leerink Eric Schmidt - Cantor Fitzgerald ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 __________________________________________________________________ FORM 10-Q __________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Num ...

bluebird bio, Inc. (NASDAQ:BLUE) Q2 2023 Earnings Conference Call August 8, 2023 8:00 AM ET Company Participants Courtney O'Leary - IR Andrew Obenshain - CEO Tom Klima - Chief Commercial and Operating Officer Chris Krawtschuk - CFO Rich Colvin - Chief Medical Officer Conference Call Participants Dane Leone - Raymond James Jason Gerberry - Bank of America Eric Joseph - JPMorgan Gena Wang - Barclays Jack Allen - Baird Luca Issi - RBC Capital Yanan Zhu - Wells Fargo Brooke Schuster - William Blair Operator Goo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 __________________________________________________________________ FORM 10-Q __________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: ...